Shasun Pharmaceuticals Ltd (SHAS.BO)
79.05INR
3:41pm IST
Rs-1.55 (-1.92%)
Rs80.40
Rs82.00
Rs82.90
Rs78.50
54,335
103,989
Rs185.90
Rs60.40
About
Overall
| Beta: | 1.51 |
| Market Cap (Mil.): | Rs4,572.38 |
| Shares Outstanding (Mil.): | 56.62 |
| Dividend: | 0.40 |
| Yield (%): | 2.97 |
Financials
| SHAS.BO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 4.39 | 34.93 | 35.13 |
| EPS (TTM): | 18.41 | -- | -- |
| ROI: | -- | 19.47 | 18.83 |
| ROE: | -- | 20.22 | 19.68 |
Shasun Pharmaceuticals falls on Vertex drug warning
Reuters Market Eye - Shasun Pharmaceuticals falls 6 percent after its Vertex Pharmaceuticals warned on Wednesday its hepatitis C drug Incivek, which is used in conjunction with two other products, can cause serious, potentially fatal skin reactions.
MARKET EYE-Shasun Pharmaceuticals falls on Vertex drug warning
* Shasun Pharmaceuticals falls 6 percent after its Vertex Pharmaceuticals warned on Wednesday its hepatitis C drug Incivek, which is used in conjunction with two other products, can cause serious, potentially fatal skin reactions. * Shasun has a long-term agreement with Vertex for supply of active pharmaceutical ingredient for the Hepatitis C drug. * "There would be incremental impact on Shasun as about 25 percent of FY13 profits were expected to come in from Incivek supply," said Surya Patra,

Estimates